Several possible studies
Story checked
]An Expert Explains Why Targeted Therapy Works (opens in a new tab)
webmd.com · 2026-05-17
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
]An Expert Explains Why Targeted Therapy Works
webmd.com · 2026-05-17
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedTargeted therapy is presented as more effective and relatively safer than chemotherapy for EGFR-mutated lung cancer, with fewer toxicities and the convenience of oral dosing.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedEGFR-mutated lung cancer is driven by changes in the EGFR gene, and targeted therapy is designed to block that driver in a precise, selective way.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedMost patients diagnosed with NSCLC are tested for mutations including EGFR, and patients are encouraged to advocate for molecular testing if it is not routinely done.View evidenceHide evidence
As statedmajority of patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedThe two most common EGFR mutations mentioned are exon 19 deletions and L858R, and the article says these have FDA-approved therapies.View evidenceHide evidence
As statedtwo most common
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedCombination approaches that pair targeted therapy with chemotherapy or other agents may increase antitumor effects, but they can also bring greater toxicity, so treatment choice depends on the individual case.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedOncogene addiction is described as the idea that EGFR-mutated cancer cells die when EGFR-targeted therapy is given, implying dependence on that signaling pathway.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedMost patients with EGFR-targeted cancer eventually develop resistance, so these therapies are unlikely to cure EGFR-mutated lung cancer even though they can provide long benefit.View evidenceHide evidence
As statedmost patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedImmunotherapy generally has not been very effective for EGFR-mutated NSCLC, so EGFR-directed targeted therapy is presented as the preferred and proven approach when an approved option exists.View evidenceHide evidence
As statedgenerally speaking
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial.
The Lancet. Respiratory Medicine · 2026 · PubMed
EGFR-T790M mutation associated with acquired resistance to first-generation EGFR tyrosine kinase inhibitors in Vietnamese Non-Small-Cell Lung Cancer patients
Vietnam Journal of Science and Technology · 2024 · Crossref
Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer.
2026 · Europe PMC
Severe Dermatologic Toxicity During Amivantamab-Lazertinib Treatment in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Cureus · 2026 · PubMed
Patritumab Deruxtecan Produces Durable Responses in Patients With Heavily Pretreated EGFR Inhibitor-Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Default Digital Object Group · 2021 · Crossref
And 10 more candidates considered.